Home About us Contact
|
Home About us Contact | ||
|
|
||
Potent Inhibition (potent + inhibition)
Selected AbstractsCritical Modifications of the ISO-1 Scaffold Improve Its Potent Inhibition of Macrophage Migration Inhibitory Factor (MIF) Tautomerase Activity.CHEMINFORM, Issue 38 2006Kai Fan Cheng Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF. [source] Potent Inhibition of Checkpoint Kinase Activity by a Hymenialdisine-Derived Indoloazepine (I).CHEMINFORM, Issue 47 2004Vasudha Sharma No abstract is available for this article. [source] Species-specific interaction of HIV protease inhibitors with accumulation of cholyl-glycylamido-fluorescein (CGamF) in sandwich-cultured hepatocytesJOURNAL OF PHARMACEUTICAL SCIENCES, Issue 6 2010Zhi-wei Ye Abstract Using sandwich-cultured hepatocytes from rat, dog, pig, and human, we investigated the species-specificity of interaction of HIV protease inhibitors (PI) with in vitro hepatic accumulation of the bile salt analogue cholyl-glycylamido-fluorescein (CGamF). Extracellular sodium depletion or coincubation with the OATP/Oatp inhibitors rifampicin and digoxin revealed that about 35% of active CGamF accumulation was mediated by Ntcp/NTCP in rat and human hepatocytes, while the contribution of this sodium-dependent transporter reached 50,60% in dog and pig hepatocytes. One or more sodium-independent transporters, likely belonging to the Oatp/OATP family, constitute a major transport mechanism for CGamF accumulation. Various HIV PI (0.5, 5, 25,µM) exhibited pronounced species differences in their interaction with active CGamF accumulation (1,µM), although some similarity was observed between the dog and human interaction profiles when HIV PI were tested at 0.5,µM. Atazanavir, indinavir, and darunavir were the most potent inhibitors of CGamF accumulation in human hepatocytes. Potent inhibition of CGamF accumulation by ritonavir in rat hepatocytes contrasted with a weak effect in human hepatocytes. Thorough characterization of in vitro disposition of probe substrates in preclinical species compared to human hepatocytes will ultimately support a better insight in species-specific mechanisms underlying drug interactions and drug-mediated toxicity. © 2009 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 99: 2886,2898, 2010 [source] Potent inhibition of in vivo angiogenesis and tumor growth by a novel cyclooxygenase-2 inhibitor, enoic acanthoic acidCANCER SCIENCE, Issue 12 2007Hye Jin Jung Recent studies have shown that cyclooxygenase-2 is crucially involved in angiogenesis. In fact, several specific cyclooxygenase-2 inhibitors suppress angiogenesis in vivo, suggesting that cyclooxygenase-2 is a promising target for the treatment of angiogenesis-related diseases. In the present study we investigate the activity of a new cyclooxygenase-2 inhibitor, enoic acanthoic acid (EAA), which was synthesized from the known natural cyclooxygenase-2 inhibitor, acanthoic acid (AA). The demonstration of a high correlation between EAA- and celecoxib-induced gene expression signatures in microarray experiments validated the specificity of EAA on cyclooxygenase-2. In angiogenesis assays, EAA potently inhibited basic fibroblast growth factor-induced invasion and tube formation of bovine aortic endothelial cells in vitro. Moreover, this inhibitor prevented both neovascularization of the chorioallantoic membrane of growing chick embryo and basic fibroblast growth factor-induced mouse corneal angiogenesis in vivo. EAA also significantly suppressed the growth of bladder tumors in a mouse model, showing better antitumor activity than celecoxib. Furthermore, gelatin zymogram analysis revealed that EAA potently inhibited the activities of matrix metalloproteinase 2 and 9. These results clearly demonstrate that EAA is a promising agent for the prevention and treatment of angiogenesis-related diseases including cancer. (Cancer Sci 2007; 98: 1943,1948) [source] Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorptionDRUG DEVELOPMENT RESEARCH, Issue 4 2002Jonathan R. Green Abstract Bisphosphonates are effective in treating benign and malignant skeletal diseases characterized by enhanced osteoclastic bone resorption (i.e., osteoporosis, Paget's disease, tumor-induced osteolysis). The nitrogen-containing bisphosphonate pamidronate is currently the standard treatment for hypercalcemia of malignancy (HCM) and skeletal complications of bone metastases. Zoledronic acid, a novel nitrogen-containing bisphosphonate with an imidazole substituent, has demonstrated more potent inhibition of osteoclast-mediated bone resorption than all other bisphosphonates, including pamidronate, in both in vitro and in vivo preclinical models. Zoledronic acid inhibited ovariectomy-induced bone loss in adult monkeys and rats, and long-term treatment prevented skeletal turnover and subsequent bone loss, reduced cortical porosity, and increased mechanical strength. Zoledronic acid also significantly inhibited bone loss associated with arthritis, bone metastases, and prosthesis loosening. The increased potency of zoledronic acid vs. pamidronate has been demonstrated clinically: zoledronic acid (4 or 8 mg iv) was superior to pamidronate (90 mg iv) in normalizing corrected serum calcium in patients with HCM. In patients with bone metastases, low doses of zoledronic acid (, 2 mg) suppressed bone resorption markers , 50% below baseline, whereas pamidronate 90 mg yielded only 20 to 30% suppression. Importantly, the increased potency of zoledronic acid is not associated with an increased incidence of local (bone) or systemic adverse events. Zoledronic acid does not impair bone mineralization and, compared with pamidronate, has a greater renal and intestinal tolerability therapeutic index. Thus, based on preclinical assays and clinical data, zoledronic acid is the most potent bisphosphonate tested to date. Given its potency and excellent safety profile, zoledronic acid is now poised to become the new standard of treatment for HCM and metastatic bone disease. Drug Dev. Res. 55:210,224, 2002. © 2002 Wiley-Liss, Inc. [source] Abstracts: The effects of Coptis japonica root extract and its key component, berberine, on human subcutaneous adipocytesINTERNATIONAL JOURNAL OF COSMETIC SCIENCE, Issue 5 2010Keiko Yashiki(Tohi) pp.274,280 An increase of subcutaneous fat presses lymph vessels and blood vessels in skin tissues, and results in not only causing skin troubles such as skin sagging and swelling but also forming cellulite that makes bodylines worse. To expand further application of plant extracts to cosmetics, we focused on inhibitory effects of subcutaneous preadipocytes differentiation and facilitating lipolysis in adipocytes. In this study, in a screening test of a number of plant extracts, Coptis japonica root extract and its key component, berberine, showed potent inhibition of triglyceride accumulation and subcutaneous preadipocytes differentiation. Furthermore, Coptis japonica root extract and berberine down-regulated the mRNA expression level of several differentiation factors derived from subcutaneous preadipocytes. Coptis japonica root extract and berberine in subcutaneous adipocytes facilitated lipolysis in mature adipocytes. Our study suggested that Coptis japonica root extract and its key component, berberine, is expected to be useful for slimming and related skin troubles such as skin sagging, swelling, cellulite, and so on. [source] Negative effects of the amino acids Lys, His, and Thr on S6K1 phosphorylation in mammary epithelial cellsJOURNAL OF CELLULAR BIOCHEMISTRY, Issue 4 2008Rotem Ladovsky Prizant Abstract The role of essential amino acids (AA) on protein synthesis via the mTOR pathway was studied in murine mammary epithelial cells cultured under lactogenic conditions. Leu, Ile, and Val increased S6K1 phosphorylation compared to that measured in AA-deprived cells. Trp, Phe, and Met had no effect. Surprisingly, Lys, His, and Thr inhibited S6K1 phosphorylation in both murine and bovine mammary cells. Thr exhibited the most potent inhibition, being the only amino acid that competed with Leu's positive role. In non-deprived cells, there was no observable effect of Lys, His, or Thr on S6K1 phosphorylation at concentrations up to five times those in the medium. However, their addition as a mix revealed a synergistic negative effect. Supplementation of Lys, His, and Thr abrogated mTOR Ser 2448 phosphorylation, with no effect on Akt Ser 473,an mTORC2 target. This confirms specific mTORC1 regulation of S6K1 phosphorylation. The individual supplementation of Lys, His, and Thr maintained a low level of IRS-1 phosphorylation, which was dose-dependently increased by their combined addition. Thus, in parallel to inhibiting S6K1 activity, these AA may act synergistically to activate an additional kinase, phosphorylating IRS-1 via an S6K1-independent pathway. In cultures supplemented by Lys, His, and Thr, cellular protein synthesis decreased by up to 65%. A more pronounced effect was observed on ,-casein synthesis. These findings indicate that positive and negative signaling from AA to the mTOR pathway, combined with modulation of insulin sensitization, mediate the synthesis rates of total and specific milk proteins in mammary epithelial cells. J. Cell. Biochem. 105: 1038,1047, 2008. © 2008 Wiley-Liss, Inc. [source] THE ROLE OF CALCIUM IN FLOW-STIMULATED BIOLUMINESCENCE OF THE RED TIDE DINOFLAGELLATE LINGULODINIUM POLYEDRUMJOURNAL OF PHYCOLOGY, Issue 2000P. Von Dassow Many marine planktonic dinoflagellates emit flashes of light in response to either laminar or turbulent flows as well as direct mechanical stimulation. The production of a flash of light is known to be mediated by a proton-mediated action potential across the vacuolar membrane; the mechanotransduction process initiating this action potential is unknown. Here we report on an investigation into the role of Ca+2 in the mechanotransduction process regulating bioluminescence in the red tide dinoflagellate Lingulodinium polyedrum. Calcium ionophores and low concentrations of the membrane-disrupting agent digitonin stimulated bioluminescence only when calcium was present in the media or added with the agent, indicating that the flash-triggering vacuolar action potential is specifically stimulated by a calcium influx. A variety of known calcium channel blockers or antagonists inhibited mechanically stimulated bioluminescence but did not affect cellular bioluminescent capacity. In many cases the inhibitory affect occurred after only a brief exposure. In addition, gadolinium (Gd+3), a blocker of many stretch-activated ion channels, caused potent inhibition of mechanically stimulated bioluminescence. The order of potency of the transition metals tested was La+3 > Gd+3 > Co+2 > Mn+2 > Ni+2, similar to their potency as blockers of known calcium channels. Experiments with a quantified shear flow demonstrated that flow-stimulated bioluminescence depended on the level of extracellular calcium. Future work will elucidate the signaling pathway involving calcium-mediated flow-stimulated mechanotransduction. Our goal is to use bioluminescence as a proxy for the initial cellular mechanotransduction events triggered by fluid flow. [source] Phage display identifies novel peptides that bind extracellular-regulated protein kinase 2 to compete with transcription factor binding,JOURNAL OF PHYSICAL ORGANIC CHEMISTRY, Issue 6-7 2004Mark A. Rainey Abstract Extracellular-regulated protein kinase 2 (ERK2) is a serine/threonine-specific protein kinase capable of phosphorylating multiple protein substrates within a cell. In an attempt to identify novel peptides that bind and inhibit the function of an active form of ERK2, phage display was carried out using a disulfide-constrained peptide library (X2CX14CX2). Several phage clones were identified by an enzyme-linked immunosorbent assay (ELISA) that competed with both a protein substrate and adenosine triphosphate (ATP) for immobilized ERK2. A chemically synthesized peptide derived from these experiments, NH2 -KKKIRCIRGWTKDIRTLADSCQY-COOH, inhibited ERK2 phosphorylation of the protein substrate Ets,138, exhibiting competitive and mixed inhibition towards Ets,138 and MgATP2,, respectively. Surprisingly, the same peptide displayed equally potent inhibition towards the phosphorylation of ATF2 by p38 MAPK,, another MAP kinase that has ,46% sequence similarity to ERK2. This study indicates that active ERK2 can be targeted by phage display to find novel antagonists to kinase function and suggests that protein-binding sites within the MAPK family may contain conserved features that render them susceptible to ligand binding. Copyright © 2004 John Wiley & Sons, Ltd. [source] Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Issue 7 2009C. VISKOV Summary.,Background and objectives: AVE5026 is a novel, hemisynthetic, ultra-low-molecular-weight heparin (ULMWH), which is in clinical development for prevention of venous thromboembolism. Its unique structural features result from the highly selective depolymerization of heparin by the phosphazene base that protects the antithrombin (AT)-binding site from destruction. In the present paper, we describe the chemical and biological characteristics of AVE5026, as well as its effects on experimental thrombosis as compared to those of the low-molecular-weight heparin (LMWH) enoxaparin after a single subcutaneous (s.c.) administration in certain animal models. Method and results: AVE5026 has a higher anti-factor Xa (anti-FXa) activity (,160 U mg,1) along with a catalytic anti-thrombin (anti-FIIa) activity (,2 U mg,1) as a result of its structure being strongly enriched in specific AT-binding oligosaccharides. In human plasma, potent inhibition of thrombin generation by AVE5026 was closely related to its anti-FXa activity. In a rat venous thrombosis model, AVE5026 showed a dose-dependent antithrombotic activity comparable to that of enoxaparin (ED50-AVE5026 = 1.6 mg kg,1, ED50-enoxaparin = 2.8 mg kg,1). Interestingly, non-occlusive venous thrombosis in rabbits was inhibited by an ED50 of 0.1 mg kg,1 AVE5026, whereas 0.316 mg kg,1 enoxaparin was not active. In a canine model, similarly to enoxaparin (ED50 = 1.3 mg kg,1), AVE5026 dose-dependently inhibited arterial thrombosis (ED50 = 2.0 mg kg,1). At equipotent doses, AVE5026 did not affect bleeding parameters, whereas enoxaparin showed increased hemorrhage in rats, rabbits and dogs. Conclusion: These unique structural attributes distinguish AVE5026 from the LMWH class. Based on these data in well-established arterial and venous thrombosis models, AVE5026 could represent a valuable alternative in thrombosis prevention with an improved benefit-risk profile as compared to that of enoxaparin. [source] Tyrosine kinase inhibitors: From rational design to clinical trialsMEDICINAL RESEARCH REVIEWS, Issue 6 2001Peter Traxler Abstract Protein kinases play a crucial role in signal transduction as well as in cellular proliferation, differentiation, and various regulatory mechanisms. The inhibition of growth related kinases, especially tyrosine kinases, might provide new therapies for diseases such as cancer. The progress made in the crystallization of protein kinases has confirmed that the ATP-binding domain of tyrosine kinases is an attractive target for drug design. Three successful examples of drug design at Novartis using a tyrosine kinase as a molecular target are described. PKI166, a pyrrolo[2,3,- d]pyrimidine derivative, is a dual inhibitor of both the EGFR and the ErbB2 kinases. The compound entered clinical trials in 1999, based on its favorable preclinical profile: potent inhibition of EGF-mediated signalling in cells, in vivo antitumor activity in several EGFR overexpressing xenograft tumor models in nude mice, long-lasting inhibition of EGF-stimulated EGFR autophosphorylation in tumor tissue, good oral bioavailability in animals, and no prohibitive in vitro and in vivo toxicity findings. The anilino-phthalazine derivative PTK787/ZK222584 (Phase I, co-developed by Schering AG, Berlin) is a potent and selective inhibitor of both the KDR and Flt-1 kinases with interesting anti-angiogenic and pharmacokinetic properties (orally bioavailable). STI571 (GlivecÔ, GleevecÔ), a phenylamino-pyrimidine derivative, is a potent inhibitor of the Abl tyrosine kinase, which is present in 95% of patients with chronic myelogenous leukemia (CML). The compound specifically inhibits proliferation of v-Abl and Bcr-Abl expressing cells (including cells from CML patients) and shows anti-tumor activity as a single agent in animal models at well-tolerated doses. Pharmacologically relevant concentrations are achieved in the plasma of animals (oral administration). Promising data from phase I and II clinical trials in CML patients (98% haematological response rate in Phase I) support the fact that the STI571 represents a new treatment modality for CML. In addition, potent inhibition of the PDGFR and c-Kit tyrosine kinases also indicates its possible clinical use in solid tumors. © 2001 John Wiley & Sons, Inc. Med Res Rev, 21, No. 6, 499,512, 2001 [source] Virucidal activity of essential oils from aromatic plants of San Luis, ArgentinaPHYTOTHERAPY RESEARCH, Issue 9 2003C. C. García Abstract Essential oils obtained from eight aromatic plants of San Luis Province, Argentina, were screened for virucidal activity against herpes simplex virus type 1 (HSV-1), Junin virus (JUNV) and dengue virus type 2 (DEN-2). The most potent inhibition was observed with the essential oil of Lippia junelliana and Lippia turbinata against JUNV with virucidal concentration 50% (VC50) values in the range 14,20 ppm, whereas Aloysia gratissima, Heterotheca latifolia and Tessaria absinthioides inhibited JUNV in the range 52,90 ppm. The virucidal activity was time- and temperature-dependent. The essential oils of A. gratissima, Artemisia douglasiana, Eupatorium patens and T. absinthioides inactivated HSV-1 at 65,125 ppm. However, only A. douglasiana and E. patens had any discernible effect on DEN-2 infectivity with VC50 values of 60 and 150 ppm, respectively. Copyright © 2003 John Wiley & Sons, Ltd. [source] In vitro Metabolism of Genistein and Tangeretin by Human and Murine Cytochrome P450sBASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY, Issue 1 2003Vibeke M. Breinholt Analysis of the metabolic profile from incubations with genistein and human liver microsomes revealed the production of five different metabolites, of which three were obtained in sufficient amounts to allow a more detailed elucidation of the structure. One of these metabolites was identified as orobol, the 3,-hydroxylated metabolite of genistein. The remaining two metabolites were also hydroxylated metabolites as evidenced by LC/MS. Orobol was the only metabolite formed after incubation with CYP1A2. The two major product peaks after incubation of tangeretin with human microsomes were identical with 4,-hydroxy-5,6,7,8-tetramethoxyflavone and 5,6-dihydroxy-4,,7,8-trimethoxyflavone, previously identified in rat urine in our laboratory. By comparison with UV spectra and LC/MS fragmentation patterns of previously obtained standards, the remaining metabolites eluting after 14, 17 and 20 min. were found to be demethylated at the 4,,7-, 4,,6-positions or hydroxylated at the 3,- and demethylated at the 4,-positions, respectively. Metabolism of tangeretin by recombinant CYP1A2, 3A4, 2D6 and 2C9 resulted in metabolic profiles that qualitatively were identical to those observed in the human microsomes. Inclusion of the CYP1A2 inhibitor fluvoxamine in the incubation mixture with human liver microsomes resulted in potent inhibition of tangeretin and genistein metabolism. Other isozymes-selective CYP inhibitors had only minor effects on tangeretin or genistein metabolism. Overall the presented observations suggest major involvement of CYP1A2 in the hepatic metabolism of these two flavonoids. [source] Folate deficiency followed by ionizing radiation perturbs hepatic dihydrofolate reducatse activityBIOFACTORS, Issue 4 2008Vipen Batra Abstract There is lot of interest in the folate metabolism because of the essential role of folate coenzymes in nucleic acid synthesis. Gamma (,) radiation is well known for inducing damage in the DNA. To counteract these damage, a variety of DNA repair pathways have evolved that require regular supply of DNA bases whose biosynthesis in turn depends on sufficient pools of folate dependent enzymes like dihydrofolate reductase (DHFR). In the present study, we examined the ionizing radiation mediated perturbation of DHFR activity in folate deficient and folate sufficient conditions. In folate deficient animals a potent inhibition of liver DHFR activity was observed. Our results showed that combination of folate starvation and ionizing radiation might adversely affect the DHFR activity, compared to their individual treatments. Measurement of apurinic/apyrimidinic sites (AP sites), a major type of DNA damage generated by radiation induced loss of purine and/or pyrimidine base, indicated a dose dependent DNA damage in folate deficient animals. In conclusion our data suggest an interactive role of folate deficiency and radiation injury in inhibiting DHFR activity. [source] Ibudilast: A Non-selective PDE Inhibitor with Multiple Actions on Blood Cells and the Vascular WallCARDIOVASCULAR THERAPEUTICS, Issue 3 2001Yukio Kishi ABSTRACT Ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) is a nonselective inhibitor of cyclic nucleotide phosphodiesterase (PDE). It is widely used in Japan for improving prognosis and relieving symptoms in patients suffering from ischemic stroke or bronchial asthma. These clinical applications are based on the properties of ibudilast that inhibit platelet aggregation, improve cerebral blood flow and attenuate allergic reactions. The inhibition of platelet aggregation and vasodilatation by ibudilast may be due to synergistic elevation of intracellular cyclic nucleotides and release of nitric oxide (NO) or prostacyclin from endothelium, rather than direct inhibition of PDE5 or PDE3. Another important property of ibudilast is its antiinflammatory activity possibly associated with potent inhibition of PDE4. Combined with its relaxing effects on bronchial smooth muscle, antiinflammatory actvity of ibudilast could favorably influence pathophysiology of asthma by antagonizing chemical mediators triggering asthmatic attacks. Ibudilast was also reported to significantly attenuate inflammatory cell infiltration in the lumbar spinal cord in an animal model of encephalomyelitis. Future investigations should include effects of ibudilast on inflammatory reactions between endothelium and blood cells, which may initiate the development of atherosclerosis. [source] The Role of Flexibility in the Rational Design of Modularly Assembled Ligands Targeting the RNAs that Cause the Myotonic DystrophiesCHEMBIOCHEM, Issue 3 2010Matthew D. Disney Prof. Abstract Modularly assembled ligands were designed to target the RNAs that cause two currently untreatable neuromuscular disorders, myotonic dystrophy types 1 (DM1) and 2 (DM2). DM1 is caused by an expanded repeating sequence of CUG, and DM2 is caused by expanded CCUG repeats. Both are present in noncoding regions and fold into hairpins with either repeating 1×1 nucleotide UU (DM1) or 2×2 nucleotide 5,-CU/3,-UC (DM2) internal loops separated by two GC pairs. The repeats are toxic because they sequester the RNA splicing regulator muscleblind-like 1 protein (MBNL1). Rational design of ligands targeting these RNAs was enabled by a database of RNA motif,ligand partners compiled by using two-dimensional combinatorial screening (2DCS). One 2DCS study found that the 6,,-azido-kanamycin A module binds internal loops similar to those found in DM1 and DM2. In order to further enhance affinity and specificity, the ligand was assembled on a peptoid backbone to precisely control valency and the distance between ligand modules. Designed compounds are more potent and specific binders to the toxic RNAs than MBNL1 and inhibit the formation of the RNA,protein complexes with nanomolar IC50 values. This study shows that three important factors govern potent inhibition: 1) the surface area sequestered by the assembled ligands; 2) the spacing between ligand modules since a longer distance is required to target DM2 RNAs than DM1 RNAs; and 3) flexibility in the modular assembly scaffold used to display the RNA-binding module. These results have impacts on the general design of assembled ligands targeting RNAs present in genomic sequence. [source] A New Indole Alkaloid and Anti-Inflammatory Constituents from Strychnos cathayensisCHEMISTRY & BIODIVERSITY, Issue 7 2008Jih-Jung Chen Abstract A new indole alkaloid, 11,12-dimethoxyhenningsamine (1), was isolated from the roots of Strychnos cathayensis, together with 19 known compounds. The structure of this new compound was determined through spectroscopic and mass-spectrometric analyses. Among the isolated compounds, 11-methoxyhenningsamine (3) and aesculetin dimethyl ether (4) exhibited potent inhibition (IC50<5.5,,g/ml) on superoxide-anion generation and elastase release by human neutrophils in response to fMet-Leu-Phe/cytochalasin B. [source] Constituents of Asarum sieboldii with Inhibitory Activity on Lipopolysaccharide (LPS)-Induced NO Production in BV-2 Microglial CellsCHEMISTRY & BIODIVERSITY, Issue 2 2008Ah-Reum Han Abstract Bioassay-guided fractionation of the root extract of Asarum sieboldii led to the isolation of the four active compounds (,)-sesamin (1), (2E,4E,8Z,10E)- N -(2-methylpropyl)dodeca-2,4,8,10-tetraenamide (2), kakuol (3), and ,3,4,5-trimethoxytoluene' (=1,2,3-trimethoxy-5-methylbenzene; 4), in terms of inhibition of lipopolysaccharide (LPS)-induced nitric oxide (NO) production. Compounds 1,4 showed potent inhibition of NO production, with IC50 values in the low nanomolar-to-micromolar range. Also isolated were the known compounds methylkakuol (5), ,3,5-dimethoxytoluene', safrole, asaricin, methyleugenol, and (,)-asarinin, which were found to be inactive in the above assay. Among the ten known isolates, compounds 1, 2, and 5 were found for the first time in this plant. [source] Discovery of Adamantyl Ethanone Derivatives as Potent 11,-Hydroxysteroid Dehydrogenase Type,1 (11,-HSD1) InhibitorsCHEMMEDCHEM, Issue 7 2010Xiangdong Su Dr. Abstract 11,-Hydroxysteroid dehydrogenases (11,-HSDs) are key enzymes regulating the pre-receptor metabolism of glucocorticoid hormones. The modulation of 11,-HSD type,1 activity with selective inhibitors has beneficial effects on various conditions including insulin resistance, dyslipidemia and obesity. Inhibition of tissue-specific glucocorticoid action by regulating 11,-HSD1 constitutes a promising treatment for metabolic and cardiovascular diseases. A series of novel adamantyl ethanone compounds was identified as potent inhibitors of human 11,-HSD1. The most active compounds identified (52, 62, 72, 92, 103 and 104) display potent inhibition of 11,-HSD1 with IC50 values in the 50,70,nM range. Compound 72 also proved to be metabolically stable when incubated with human liver microsomes. Furthermore, compound 72 showed very weak inhibitory activity for human cytochrome P450 enzymes and is therefore a candidate for in,vivo studies. Comparison of the publicly available X-ray crystal structures of human 11,-HSD1 led to docking studies of the potent compounds, revealing how these molecules may interact with the enzyme and cofactor. [source] Synthesis of the active stilbenoids by photooxidation reaction of trans-,-viniferinCHINESE JOURNAL OF CHEMISTRY, Issue 11 2004Chun-Suo Yao Abstract Two new stilbenoids, cis -,-viniferin (3) and 2b, 14b-dehydro-bisresveratrol (4) were synthesized by photooxidation reaction of trans -,-viniferin (2) prepared from tram-resveratrol (1). Pentamethoxyl trans -,-viniferin (5) and pentamethoxyl cis -,-viniferin (6) were also obtained by methylation of trans -,-viniferin (2) with (MeO)2SO2. Their structures were elucidated on the basis of spectral evidence. Compounds 3 and 4 showed potent inhibition of TNF-, at concentrations of 10, - 5 mol.L,1 with inhibitory ratios of 51.43% and 36.64%. respectively. [source] | ||||||||||||||||